Natco Pharma reported a consolidated net profit of ₹206.5 crore for the quarter ended June 30, 2026, a significant decline from the ₹480.3 crore recorded in the corresponding quarter of the previous fiscal year. The Hyderabad-based pharmaceutical company’s consolidated total revenue dropped 43% year-on-year to ₹794.4 crore, compared to ₹1,390.6 crore in Q1FY26.

The sharp contraction in top-line growth was largely attributable to lower revenue from Lenalidomide, a key specialty oncology product. This decline was partially offset by growth in the company’s base business segments. Despite the revenue drop, the company maintained profitability, supported by contributions from its associate company and other operating income.

Financial Performance Breakdown

The financial results highlight a divergence between the core pharma business and the associate company’s performance. While domestic and international formulation revenues faced headwinds, the associate company, Adcock Ingram Holdings Limited, contributed significantly to the bottom line.

International formulations, which include profit share and subsidiaries, accounted for the largest portion of revenue at ₹477.1 crore, down from ₹1,120.9 crore in the prior year. Conversely, domestic pharmaceutical formulations grew 28% year-on-year to ₹136.4 crore from ₹107.0 crore. Active Pharmaceutical Ingredients (API) revenue also expanded to ₹66.7 crore from ₹52.6 crore.

Associate Company Contribution

A critical component of Natco Pharma’s profitability this quarter came from its associate, Adcock Ingram Holdings Limited in South Africa. Adcock Ingram reported revenue of ₹1,582.8 crore and a profit after tax of ₹242.2 crore for the quarter. Natco Pharma’s share of this profit, based on its 35.75% holding as of June 30, 2026, stood at ₹84.3 crore.

In July 2026, Natco Pharma acquired an additional 13.25% stake in Adcock Ingram, increasing its total holding to 49%. This acquisition, completed through its wholly-owned subsidiary Natco Pharma South Africa Proprietary Limited, involved a purchase consideration of ZAR 1,814.74 million (approximately ₹10,600 million).

What the Numbers Show

The data reveals a heavy reliance on non-core or associate profits to sustain overall net income amidst a severe contraction in core international formulation revenues. With international formulation revenue plummeting by over 57% year-on-year, the ₹84.3 crore share of profit from Adcock Ingram represented approximately 41% of the total consolidated net profit of ₹206.5 crore. This underscores the strategic importance of the South African associate in stabilizing earnings during a period of weakness in the primary US-focused oncology pipeline.

Corporate Actions and Dividend

The Board of Directors declared an interim dividend of ₹1.50 per equity share of face value ₹2 each for the financial year 2026-27. Shareholders on record as of August 20, 2026, will be eligible for the payout, with payments commencing on August 26, 2026.

Additionally, the Board approved the exploration of raising funds up to ₹2,000 crore through various instruments, including public issues, preferential issues, rights issues, or private placements. This capital raise is subject to necessary regulatory and shareholder approvals. The Board also approved the notice for the 43rd Annual General Meeting and authorized the Chairman and Managing Director to fix the date and time for the event via video conference or other audio-visual means.

Natco Pharma reported a significant contraction in its first-quarter financial performance, with both top-line and bottom-line figures declining sharply compared to the same period last year.

The company’s net profit for the quarter stood at ₹2.1 billion, down from ₹4.8 billion recorded in the corresponding period of the previous fiscal year. This represents a substantial year-on-year decline in profitability.

Financial Performance

Revenue also witnessed a steep drop, falling to ₹7.3 billion from ₹13.3 billion in the prior year quarter. The decline in sales was accompanied by a compression in operating margins.

EBITDA for the quarter was ₹1.86 billion, a significant decrease from ₹5.7 billion in the previous year. Consequently, the EBITDA margin contracted to 25.4% from 42.97% recorded earlier.

What the Numbers Show

The data reveals a divergence between the rate of revenue decline and the sharper contraction in operating profits. While revenue fell by approximately 45%, EBITDA declined by nearly 67%. This suggests that cost structures or input prices may not have reduced proportionately with the drop in sales volume, leading to significant margin pressure during the quarter.